Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Alameddine R, Husari A.

N Engl J Med. 2013 May 16;368(20):1944-5. doi: 10.1056/NEJMc1303641#SA1. No abstract available.

PMID:
23675666
2.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Vink R, Sohne M.

N Engl J Med. 2013 May 16;368(20):1945. doi: 10.1056/NEJMc1303641#SA3. No abstract available.

PMID:
23675668
3.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Derksen RJ, Mulder WM, Mulder JW.

N Engl J Med. 2013 May 16;368(20):1945. doi: 10.1056/NEJMc1303641#SA2. No abstract available.

PMID:
23675667
4.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Spyropoulos AC; MAGELLAN Steering Committee..

N Engl J Med. 2013 May 16;368(20):1945-6. doi: 10.1056/NEJMc1303641. No abstract available.

5.

[Rivaroxaban for thromboprophylaxis inpatients with acute medical illness].

Ruiz Muñoz M.

Rev Clin Esp (Barc). 2013 Jun-Jul;213(5):257. Spanish. No abstract available.

PMID:
23940851
6.

Rivaroxaban for thromboprophylaxis.

Lotke PA.

N Engl J Med. 2008 Nov 13;359(20):2174; author reply 2175-6. No abstract available.

PMID:
19009675
7.

Rivaroxaban for thromboprophylaxis in acutely ill medical patients.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; MAGELLAN Investigators..

N Engl J Med. 2013 Feb 7;368(6):513-23. doi: 10.1056/NEJMoa1111096.

8.

Rivaroxaban for thromboprophylaxis.

Schuman EP.

N Engl J Med. 2008 Nov 13;359(20):2174; author reply 2175-6. doi: 10.1056/NEJMc081524. No abstract available.

9.

Rivaroxaban for thromboprophylaxis.

ten Cate H, Hamulyak K.

N Engl J Med. 2008 Nov 13;359(20):2174-5; author reply 2176. No abstract available.

PMID:
19009676
10.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators..

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

11.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group..

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

12.

Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.

Loke YK, Kwok CS.

J Clin Pharm Ther. 2011 Feb;36(1):111-24. doi: 10.1111/j.1365-2710.2010.01162.x. Review.

PMID:
21198726
13.

New anticoagulants--the path from discovery to clinical practice.

Lohrmann J, Becker RC.

N Engl J Med. 2008 Jun 26;358(26):2827-9. doi: 10.1056/NEJMe0804291. No abstract available.

PMID:
18579818
14.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.

Cao YB, Zhang JD, Shen H, Jiang YY.

Eur J Clin Pharmacol. 2010 Nov;66(11):1099-108. doi: 10.1007/s00228-010-0889-z.

PMID:
20812009
15.

Oral rivaroxaban for symptomatic venous thromboembolism.

EINSTEIN Investigators., Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.

N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903.

16.

Rivaroxaban for thromboprophylaxis.

Lippi G, Franchini M, Targher G.

N Engl J Med. 2008 Nov 13;359(20):2174; author reply 2175-6. No abstract available.

PMID:
19009674
17.

Selective factor Xa inhibition for thromboprophylaxis.

Eikelboom JW, Weitz JI.

Lancet. 2008 Jul 5;372(9632):6-8. doi: 10.1016/S0140-6736(08)60879-X. No abstract available.

PMID:
18582929
18.

Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.

Kwong LM.

Am J Manag Care. 2011 Feb;17(1 Suppl):S22-6. Review.

19.

Therapeutic potential of oral factor Xa inhibitors.

Hylek EM.

N Engl J Med. 2010 Dec 23;363(26):2559-61. doi: 10.1056/NEJMe1012149. No abstract available.

PMID:
21175319
20.

Rivaroxaban, the first oral, direct factor Xa inhibitor.

Fassiadis N.

Expert Opin Pharmacother. 2009 Dec;10(18):2945-6. doi: 10.1517/14656560903413559.

PMID:
19925048
Items per page

Supplemental Content

Support Center